Biotech entity
All 2 tracked stories fall under one category: pharma. Alcon is most often covered alongside Allison Transmission, which appears in 1 of these 2 stories. Each carries 4 original sources on average. We currently track 2 Biotech stories that mention Alcon, all published on February 25, 2026.
Last mentioned: Mar 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: pharma. Alcon is most often covered alongside Allison Transmission, which appears in 1 of these 2 stories. Each carries 4 original sources on average. We currently track 2 Biotech stories that mention Alcon, all published on February 25, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Alcon. Shared-story counts are live from our verified record — not editorial picks.
Alcon (ALC) reported Q4 2025 revenue of $2.7 billion and non-GAAP EPS of $0.78, both narrowly missing analyst estimates. Despite the slight financial shortfall, the eye care leader maintains a strong market position in surgical innovation and vision care products.
Alcon reported a core EPS of $0.78 for the fourth quarter, slightly missing the FactSet consensus estimate of $0.79. The results highlight a period of consolidation for the eye care leader as it navigates the post-spinoff landscape and competitive pressures in surgical and vision care.
Alcon is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
